Literature DB >> 34155708

Evaluation of more than one billion outpatient prescriptions and eight-year trend showing a remarkable reduction in antibiotic prescription in Turkey: A success model of governmental interventions at national level.

Mesil Aksoy1, Fatma Isli1, Esma Kadi1, Didem Varimli1, Hakki Gursoz1, Tolga Tolunay1, Ates Kara2, Serhat Unal2, Emine Alp Mese3.   

Abstract

PURPOSE: To present the antibiotic prescription trend between 2011-2018 at primary healthcare in Turkey in order to evaluate the effects of interventions at national level for providing rational prescription of antibiotics.
METHODS: Electronic prescription data of the family physicians collected from January 1, 2011 to December 31, 2018 in 81 provinces of Turkey were recorded through the Prescription Information System and screened for the antimicrobial drugs. The interventions to promote rational antibiotic use during 2011-2018 in Turkey includes reminding the legislation to stop access of antibiotics without prescription, monitoring of antibiotic prescription behaviors of primary healthcare physicians, and education of healthcare workers and the public on the appropriate use of antibiotics.
RESULTS: A total of 1 054 261 396 prescriptions for outpatients of all age groups were recorded during this period. Of the prescriptions written by family physcians, 34.94% were containing at least one antibiotic in 2011, which declined to 24.55% in 2018. Antibiotics constituted 13.99% of all the items in prescriptions in 2011 and 10.47% in 2018. Percentage of total antibiotic expenditure to the total drug expanditure decreased from 14.14% to 4.12% during 2011-2018. The most commonly prescribed antibiotics were amoxicillin and enzyme inhibitor combination, cefdinir, and cefuroxime during 2011-2018, with an increasing trend for prescription of first-line antibiotic, amoxicillin, in recent years.
CONCLUSIONS: Governmental interventions at national level have contributed to reducing antibiotic prescription and increasing preference of first-line antibiotics at primary healthcare level in Turkey over a course of 8 years. Turkey's model of governmental interventions may set an example for other countries with high consumption of antibiotics, and contribute to the actions against antimicrobial resistance worldwide.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  antibiotic usage; antibiotics; electronic system; intervention; prescription

Mesh:

Substances:

Year:  2021        PMID: 34155708     DOI: 10.1002/pds.5311

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  4 in total

1.  Increasing rates of extended-spectrum B-lactamase-producing Escherichia coli and Klebsiella pneumoniae in uncomplicated and complicated acute pyelonephritis and evaluation of empirical treatments based on culture results.

Authors:  Bircan Kayaaslan; Zeynep Oktay; Imran Hasanoglu; Ayse Kaya Kalem; Fatma Eser; Muge Ayhan; Rahmet Guner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-01-03       Impact factor: 3.267

2.  Short-acting β2-agonist prescription patterns in patients with asthma in Turkey: results from SABINA III.

Authors:  Arzu Yorgancıoğlu; Kurtuluş Aksu; Sibel Atış Naycı; Dane Ediger; Dilşad Mungan; Umut Gül; Maarten J H I Beekman
Journal:  BMC Pulm Med       Date:  2022-06-02       Impact factor: 3.320

3.  Good versus poor prescribers: the comparison of prescribing competencies in primary care.

Authors:  Omer Atac; Volkan Aydin; Selma Karabey; Osman Hayran; Ahmet Akici
Journal:  Prim Health Care Res Dev       Date:  2022-03-28       Impact factor: 1.458

4.  Country data on AMR in Türkiye in the context of community-acquired respiratory tract infections: links between antibiotic susceptibility, local and international antibiotic prescribing guidelines, access to medicine and clinical outcome.

Authors:  Didem Torumkuney; Zerrin Aktas; Serhat Unal; James van Hasselt; Yalcin Seyhun; Nergis Keles
Journal:  J Antimicrob Chemother       Date:  2022-09-06       Impact factor: 5.758

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.